Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06585514 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

StatusRecruiting
PhasePhase 1/2
Started2024-10-17
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 10, 2026 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2026-03-06
Study Status, Oversight v3
Primary completion date2025-09-30→2026-09-30
Completion date2025-12-31→2026-12-31
2025-09-16
Study Status, Oversight v2
Re-verified, no change to tracked fields
2024-11-07
Not Yet Recruiting→Recruiting Study Status, Oversight, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-10-01→confirmed 2024-10-17
Study sitesdetails revised at 1 of 1 site
2024-09-03
Original filing
The goal of this study is to evaluate the safety and efficacy of CD19 CAR T cells in the treatment of Systemic lupus erythematosus (SLE).
Trial Details
NCT Number NCT06585514
Lead Sponsor Beijing GoBroad Hospital
Conditions Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Enrollment 18 participants
Start Date 2024-10-17
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-10